How to use this page
This is not a second study guide. It is a record of what Professor Webster told the class to study for Exam 2, on 16 October 2026, in the last twenty minutes of the Epidemiology lecture. It opens “This is for the exam” [part 4, 0:00]. She walked her three Exam 2 lectures in order: Disorders in Immunity objective by objective, the Gram-positive bacilli organism by organism, and Epidemiology as a short closing list.
Each item carries her words and then the answer from the slides, cited to the slide. Her words are quoted only where both transcripts of the recording agree, and the time in brackets says where they are: [part 4, 13:17] is thirteen minutes into the review. For Epidemiology she had flagged things during that morning’s lecture itself, so those are quoted too, in a separate box marked In the lecture, with their part of the recording. The recording only decides the weighting. Every fact comes from the slides — the visible text and pictures, never the speaker notes — and where what she said differs from a slide, the page says so and teaches the slide.
| Tier | What it means |
|---|---|
| Know cold | She asked the class to answer it, drilled it, or said “need to know”, “should know” or “should be able to” (for Epidemiology, in the lecture as well as the review) |
| Know it | She walked it without singling it out — or it is an objective she did not mention, and its box says so plainly |
| Light touch | She said not to memorize it |
Scope. She reviewed only the three lectures she taught — Lecture 7 (Disorders in Immunity), Lecture 10 (Gram-Positive Bacilli of Medical Importance) and Lecture 12 (Epidemiology). Exam 2, on Friday 23 October 2026, covers Lectures 7–13, so Dr. Fair’s four lectures are examinable and are not on this page: Lecture 8 (Diagnosing Infections), Lecture 9 (Cocci of Medical Importance), Lecture 11 (Novel Antimicrobial Therapy) and Lecture 13 (Miscellaneous Bacterial Agents of Disease). Use the full Exam 2 study guide and the cram sheet for those. The five master exam forms draw from all seven lectures by class time, and every form carries at least one question on each of her “know cold” items.
She also skipped parts of her own lectures, and they are still objectives: in Lecture 7, the mechanisms of carcinogenesis (Objective 8) and how allergy is diagnosed; in Lecture 10, Nocardia and the modes of transmission (Objective 2); in Lecture 12, the uses of epidemiology training, the sources of data and the definition of a reportable disease (Objectives 2, 4 and 6), and every application in Objective 10 except policy. Each has its place below, with a plain note that she did not mention it.
Lecture numbering. The site and the class calendar call the Gram-positive bacilli lecture Lecture 10, and so does this page; its deck file is named “Lecture 9 Dr. Webster Gram positive Bacilli.pptx”. Slide numbers are that file’s.
All three were said during the Epidemiology lecture, about slides, not objectives:
- The Slide 13 graph of genetic susceptibility to cancer over the lifespan — “which I’m not asking you to memorize” [part 1, 11:25]. Item 3.3.
- The Slide 23 list of notifiable diseases — “a list I’m absolutely not requiring you to pay attention to” [part 1, 27:48]. The definition of a reportable disease is still Objective 6; item 3.6.
- The Slide 25 list of uses of surveillance data — “I don’t want you to memorize this list” [part 1, 29:10]. Item 3.5.
She was reviewing from memory at speed. In each of these the slide wins, and the item explains:
- 1.3 Allergy shots: the blocking IgG (immunoglobulin G) keeps the allergen away from the IgE (immunoglobulin E) on mast cells; it is not that the IgE can no longer be made.
- 1.4 Rh disease: the slide’s condition is an Rh-negative mother with an Rh-positive fetus.
- 1.6 Rheumatic fever gives arthritis, myocarditis and valve scarring; “reactive arthritis” is a different example (Shigella, Salmonella, Campylobacter).
- 1.7 Secondary immunodeficiency: the slide’s causes include blood cell cancers, not cannabis.
- 2.1 Anthrax: the slides have four forms (injection too) and anthrax meningitis, not three.
- 2.4 Tetanus: the slides say strict anaerobe needing low oxygen tension; “mixed infection” is the myonecrosis slide’s term.
- 2.7 Listeria is resistant to cold and grows in the refrigerator; it does not need cold. Cold enrichment is the laboratory culture method.
- 2.11 Leprosy: armadillo transmission is a possibility; the mechanism is not fully verified.
- 2.12 Actinomyces: abdominal actinomycosis is a complication of a burst appendix, not a cause of appendicitis.
1 · Lecture 7 — Disorders in Immunity
Instructional objectives — Disorders in Immunity
- Describe the types of immunopathologies.
- Compare and contrast the types of hypersensitivities and diseases caused by hypersensitivity conditions.
- Describe the primary methods of diagnosing, treating, and preventing allergies.
- Describe the mechanism of transfusion reactions.
- Explain the immunology of transplantations and tissue histocompatibility.
- Describe etiology autoimmune conditions.
- Differentiate between primary and secondary immunodeficiency conditions.
- Explain the mechanisms of carcinogenesis.
- Compare and contrast immunotherapy strategies.
She walked this lecture objective by objective, in order, asking the class for most of the answers. One item per objective follows.
1.1 · Objective 1 — The types of immunopathologies Know it
“My chapters on this are the immune disorders. … Different types of immunopathologies.” [part 4, 0:02–0:08] She read the objective and went straight on to the hypersensitivities; she asked nothing about it.
One slide answers this objective, and it is the frame for the whole lecture: every disorder is either the immune system doing too much or too little. Lecture 7, Slide 3.
| Immunopathology | What it is | Over or under |
|---|---|---|
| Allergy, hypersensitivity | An exaggerated, misdirected expression of immune responses to an allergen (antigen), using the same mechanisms as protective immune reactions. Four types: I, II and III are B cell mediated; IV is T cell mediated | Overreaction |
| Autoimmunity | Abnormal responses to self antigen | Typically overreaction |
| Immunodeficiency | Deficiency or loss of immunity | Underreaction |
| Cancer | Both a cause and an effect of immune dysfunction | Underreaction |
The overview picture draws the same split: overreaction leads to the four hypersensitivities (B cells for types I–III, T cells for type IV); underreaction or loss of immunity leads to immunodeficiency; lack of surveillance leads to cancer. Lecture 7, Slide 4.
The rest of this section follows that split. Items 1.2–1.6 are overreactions; items 1.7–1.9 are underreactions and cancer.
1.2 · Objective 2 — The four hypersensitivities Know cold
“The types of hypersensitivities and the diseases caused by them. Remember, we have four different hypersensitivity types. You need to be able to identify their mechanisms and example diseases.” [part 4, 0:13–0:23] Then she asked for each type in turn: “What is type one?” [0:30] … “What’s type two?” [1:24] … “What happens in a type three hypersensitivity? … But what’s the mechanism of action?” [5:15–5:23] … “And then what is a type four hypersensitivity?” [6:13]
“You need to be able to” is the strongest instruction she gave for this lecture, and she named the two things to be able to do: the mechanism and an example disease. The slide’s table has exactly those columns.
| Type | Mechanism | Examples |
|---|---|---|
| I | IgE (immunoglobulin E) mediated, immediate. Cell-bound antibody is crosslinked and releases inflammatory mediators; mast cells, basophils and eosinophils are involved | Hay fever, hives, anaphylactic shock |
| II | Initiated by IgG (immunoglobulin G) and IgM (immunoglobulin M). Free antibody binds cell-surface antigens; complement is activated; cell lysis by the membrane attack complex, and phagocytosis | Transfusion reactions |
| III | Initiated by IgG and IgM. Free antibody binds soluble antigens, forming immune complexes that embed in basement membranes and start an inflammatory condition (phagocytosis and complement activation) | Serum sickness; autoimmune conditions such as lupus |
| IV | Delayed hypersensitivity; T cell mediated; cytotoxic cells destroy tissue | Contact dermatitis |
Lecture 7, Slide 9.
Her one-line version of each type, which is the way to carry them into the exam: type I is IgE on mast cells; type II is IgG or IgM plus complement punching holes in a cell (“Complement has the membrane attack complex that will then punch holes into membranes” [part 4, 1:48]); type III is antigen-antibody complexes lodging in basement membranes and setting up inflammation; type IV is “no antibodies, T cells” [part 4, 6:23]. The question to ask of any example is whether there is an antibody, and if so whether it binds a cell (II) or a soluble antigen (III).
Type I in more detail
Sensitizing dose: on first contact with the allergen, specific B cells form IgE, which attaches to mast cells and basophils; generally no signs or symptoms. Provocative dose: later exposure to the same allergen binds the IgE–mast cell complex (each cell can bind 10,000–40,000 IgE) and the mast cells degranulate, releasing inflammatory cytokines. General targets are the skin, upper respiratory tract, gastrointestinal tract and conjunctiva (rashes, itching, redness, rhinitis, sneezing, diarrhea, tears); systemic targets are smooth muscle, mucous glands and nervous tissue (vascular dilation and constriction changing blood pressure and respiration). Lecture 7, Slide 12.
The mediators drawn on the degranulation diagram are histamine, serotonin and bradykinin, prostaglandins and leukotrienes. Lecture 7, Slide 14. The wheal and flare skin reaction is cutaneous anaphylaxis and is used in diagnosis Lecture 7, Slide 20; systemic anaphylaxis is sudden respiratory and circulatory disruption that can be fatal in minutes Lecture 7, Slide 21. About six hours after the immediate reaction a late-phase reaction follows, mediated by synthesized products such as leukotrienes and drawing in eosinophils. Lecture 7, Slide 23.
Her aside, not on a slide. She named heparin with histamine and the prostaglandins, and gave a mosquito bite as a wheal-and-flare example [part 4, 0:51–1:05]. Neither is on a slide; the slide’s mediators are the five named above.
Type II, type III and type IV in more detail
Type II reactions lyse foreign cells: antibodies of the IgG or IgM class stimulate complement, leading to lysis. Examples: transfusion reactions (ABO blood groups; the Rh factor and hemolytic disease of the newborn) and some autoimmune diseases — autoimmune hemolytic anemia, and myasthenia gravis against acetylcholine receptors. Lecture 7, Slide 32.
Type III: antigen-antibody reaction of IgG and IgM (sometimes IgA, immunoglobulin A) with complement; the complexes deposit in the basement membranes of epithelial tissues, are trapped, and incite a damaging inflammatory response. It requires a large amount of antigen; symptoms are delayed by hours to days; joint, skin and kidney involvement are typical. Lecture 7, Slide 38. Examples: serum sickness (foreign animal proteins such as horse serum for tetanus, or animal hormones or drugs; complexes in the heart, kidneys, skin and joints); the Arthus reaction (localized dermal injury from inflamed blood vessels, a vasculitis, after a second injection of vaccine at a site; normally self-limiting); and autoimmune disorders — post-streptococcal glomerulonephritis, systemic lupus erythematosus and rheumatoid arthritis. Lecture 7, Slide 39.
Type IV: delayed hypersensitivity, T cell mediated — a delayed response to antigen involving activation of, and damage by, T cells. Infectious allergy: tuberculosis, leprosy, syphilis, histoplasmosis, toxoplasmosis, candidiasis. Skin responses: the tuberculin skin test, and contact dermatitis from plants, metals and cosmetics. And graft rejection. Lecture 7, Slide 40. In contact dermatitis the first contact is the sensitizing dose; later contact is the reactive dose, with tissue damage from macrophage cytokines and cytotoxic T cells. Lecture 7, Slide 42.
Timing, and a word trap. The Lecture 7 slides give no hours for type IV. The hours are on the Lecture 10 tuberculosis slide: the Mantoux test is read for a red wheal (induration) at 48–72 hours Lecture 10, Slide 76. — which is what she said (“48 to 72 hours after you’re exposed” [part 4, 6:53]). Note that the slides also call type III symptoms “delayed — hours to days” Lecture 7, Slide 38; the name delayed hypersensitivity belongs to type IV, so do not let the word alone decide an answer.
Her aside, not on a slide. Her reason for the delay, “it takes 48 hours or so to develop the new effector T cells” [part 4, 6:45], is not on a slide.
One crossover worth knowing: allergic asthma starts as a type I response (crosslinking of IgE on mast cells by inhaled allergen) but leads to chronic asthma, which the slide labels type IV, mediated by cytokines and eosinophil granules. Lecture 7, Slide 19.
1.3 · Objective 3 — Diagnosing, treating and preventing allergies Know cold
“If you wanted to treat a type one allergy, how do you treat type one allergies … You can also take different kinds of medications, but the medications are typically against some of those substances that are released. We’re talking about things like antihistamines. … But what can you do to try to really quell that? You go through the desensitization, the allergy shots, and what are you trying to do when you get allergy shots? You’re trying to train your body to produce what? Defensive IgG antibodies against the allergen.” [part 4, 3:42–4:47]
She asked two questions here, and both were about treatment. Management of type I hypersensitivity has three general methods: prevention, pharmacological control and desensitization. Lecture 7, Slide 26.
Prevention
Modify the environment, modify behaviors, avoid exposure to the allergen. Lecture 7, Slide 27.
Pharmacological control — drugs that block lymphocytes, mast cells or mediators
| Drug | What it does |
|---|---|
| Antihistamines | Bind to histamine receptors on target organs |
| Corticosteroids | Inhibit lymphocytes to reduce IgE |
| Cromolyn sodium | Blocks degranulation |
| Montelukast sodium | Blocks synthesis of leukotriene |
| Omalizumab | Monoclonal antibody against IgE |
| Epinephrine | Reverses airway constriction, re-establishes tight junctions in the endothelium |
Lecture 7, Slide 28. In systemic anaphylaxis epinephrine also relaxes bronchial smooth muscle, prevents or decreases upper airway mucosal edema, stimulates the heart, and binds receptors on immune cells to suppress histamine release. Lecture 7, Slide 22.
Desensitization — her “allergy shots”
Allergen-specific immunotherapy. The most common form is subcutaneous immunotherapy: small amounts of the allergen are injected, which may stimulate high levels of allergen-specific IgG that block the allergen from the IgE, so the mast cells do not degranulate. It improves reactions in about 80% of those who go through it. Lecture 7, Slide 29. The slide adds that “it’s not that simple”: regulatory T cells are activated that inhibit T cell activation of B cells and release cytokines that reduce inflammation, and mediators are induced that damp local allergic inflammation. Lecture 7, Slide 30. Sublingual immunotherapy puts the allergen under the tongue as a dissolvable tablet or liquid extract; it is used more outside the United States, though tablets are approved in the United States for pollen and dust mite allergens, and trials show it effective for peanut, kiwi, hazelnut, milk and peach allergies. Lecture 7, Slide 31.
Her words and the slide differ; the slide wins. She finished the point with “So you have more IgG defensive ones so that it can’t make the IgE that will cause the mast cells to rupture” [part 4, 4:47]. The slide’s mechanism is that the blocking IgG intercepts the allergen before it reaches the IgE already on the mast cells, so the mast cells do not degranulate. Lecture 7, Slide 29. Learn the slide’s version: the IgE is still there; the allergen never gets to it.
Diagnosing allergy
Not in her review, still examinable. The objective asks for diagnosis as well as treatment and prevention, and she did not mention diagnosis. It is on one slide. Lecture 7, Slide 25.
- First, it is important to determine whether a person is experiencing allergy or infection.
- Skin testing — wheal and flare reactions: skin prick testing and intradermal testing.
- Blood tests — specific IgE; increased basophils.
- Physician-supervised challenge — for food allergies when other tests are inconclusive.
- Patch test — typically for contact dermatitis, which is type IV.
Lecture 7, Slide 25.
1.4 · Objective 4 — Transfusion reactions: ABO and Rh Know cold
“So here we were talking about transfusion reactions. The ABO blood typing reactions. And so you should know, you know, what is compatible for donor and recipient … what is not compatible for donor and recipient.” [part 4, 1:59–2:18] Then Rh, as a question: “Rh incompatibility. When does that occur? … Mother is negative. Rh negative. Father is positive. And so first pregnancies are okay. But first pregnancies can sensitize the mother to the Rh factors.” [part 4, 2:33–3:04] … “But what can you do to prevent that from happening?” A student answered, and she confirmed: “Exactly right.” [part 4, 3:29–3:35]
“You should know” is a direct instruction, and it was about compatibility. Both of her examples are type II reactions: antibody binding a cell and complement lysing it.
ABO — the rule the slide gives
- Donors and recipients are matched for the A, B, O system of blood group antigens. There are no major histocompatibility complex molecules on red blood cells, so ABO is what is critical to match.
- You carry antibodies in your serum against the ABO antigens you lack.
- Crossmatching confirms compatibility. Transfusions are temporary.
- ABO incompatibilities can be fatal, because of complement activation and cell lysis.
Lecture 7, Slide 33.
The cross-match test: the recipient’s serum is tested against the donor’s red cells. The reverse is not done, because even with whole blood there is not enough donor antibody to coat the recipient’s cells densely enough for a reaction. Lecture 7, Slide 34. What a reaction does: destruction of red cells, blockage of the glomeruli, fever and jaundice; and even if complement activation is incomplete, antibody-coated cells may attract natural killer cells or macrophages. Lecture 7, Slide 35.
What the deck gives. She asked the class to know what is compatible for donor and recipient, but the deck has no compatibility chart; it gives the rule on Slide 33 (and a picture of red cells). The table below is that rule applied, nothing more: a donor’s red cells are incompatible when they carry an ABO antigen the recipient’s own cells lack, because the recipient’s serum has antibody against it. Lecture 7, Slide 33.
| Recipient’s red cells carry | So the recipient’s serum has antibody against | Donor red cells that are compatible |
|---|---|---|
| A | B | O or A |
| B | A | O or B |
| A and B | Neither | O, A, B or AB |
| Neither (type O) | A and B | O only |
Rh and hemolytic disease of the newborn
- The Rh antigen is present on Rh-positive red cells and not on Rh-negative cells. An Rh-negative person does not produce anti-Rh antibody unless sensitized — by a bad transfusion or an incompatible pregnancy.
- Hemolytic disease of the newborn (erythroblastosis fetalis) occurs with an Rh-negative mother and an Rh-positive fetus.
- The first pregnancy is normally fine — it is the sensitization. Subsequent pregnancies have the potential to be hemolytic.
- Prevention is passive immunization with antibodies against the Rh antigen (Rhogam), which prevents sensitization of the mother.
Lecture 7, Slide 36. Rhogam is given at 26–28 weeks of pregnancy, within 72 hours after birth, and after prenatal invasive tests, abdominal injury or accidental exposure. Lecture 7, Slide 37.
Her words and the slide differ; the slide wins. She put the condition as “Mother is negative … Father is positive” [part 4, 2:46–2:50]. The slide states it as an Rh-negative mother with an Rh-positive fetus. Lecture 7, Slide 36. A positive father is how the fetus can be positive, but the fetus’s type is what the slide’s condition, and an exam stem, turns on.
Her aside, not on a slide. She added that the mother’s anti-Rh antibody “goes across, it’s an IgG, goes across the placenta” [part 4, 3:16–3:21]. The Rh slides do not say which class of antibody it is or that it crosses the placenta.
1.5 · Objective 5 — Transplantation and histocompatibility Know it
“We talked about transplantations and tissue histocompatibility. … Remember that you are trying to match up the MHC [major histocompatibility complex] or HLA [human leukocyte antigen] antigens when you’re talking about donor versus recipient, and that there are different kinds of rejections that you can have. … So go back and look over those rejection types. The hyperacute is a type two. The acute is a type four. The chronic is a type three.” [part 4, 7:07–7:54] “Remember that the chronic was one that we often attribute … failures of heart and kidney grafts over a long period of time.” [part 4, 8:00–8:04]
She told the class to go back to the rejection types and then gave the answer herself. Her mapping matches the slide exactly.
| Problem with a solid organ transplant | Hypersensitivity type | What the slides add |
|---|---|---|
| Hyperacute rejection | Type II | Pictured as a swollen, dark, failed kidney in surgery Lecture 7, Slide 45. |
| Acute rejection | Type IV | Effector T cells respond to human leukocyte antigen differences between donor and recipient. The picture: dendritic cells in the kidney graft migrate to the spleen and activate effector T cells, which travel to the graft in the blood and destroy it Lecture 7, Slide 46. |
| Chronic rejection | Type III | Occurs months or years after transplantation; thickening of the vessel wall makes the blood supply inadequate; causes failure of more than half of all kidney and heart transplants after 10 years or more Lecture 7, Slide 47. |
| Graft versus host disease | Type IV | Not in her review: see below |
Lecture 7, Slide 44.
Hyperacute II, acute IV, chronic III. The numbers do not run in order of speed, which is exactly why she told the class to go back and look. She did not ask the room for it; she said it, so it sits in the Know it tier, but it is the single most quotable fact in this objective.
The rest of the objective
Graft or transplantation rejection runs both ways: the host may reject the graft, and the graft may reject the host. It is associated with the major histocompatibility complex, and different grafts succeed differently because of compatibility. Autograft: a self graft (skin, gum, vein). Isograft: from a genetically identical twin. Allograft: from a member of the same species. Xenograft: from another species. Lecture 7, Slide 43.
| Tissue | Matching requirement |
|---|---|
| Cornea | The first organ successfully transplanted. The eye has evolved tolerance mechanisms (down-regulating T cells, macrophages, neutrophils and complement) so it succeeds even without a human leukocyte antigen match |
| Liver | Succeeds across human leukocyte antigen differences; human leukocyte antigen is not assessed but ABO blood group is; hepatocytes carry very little class I and no class II |
| Bone marrow | Most sensitive to human leukocyte antigen discrepancies, which can lead to graft versus host disease: donor cells attack host tissue, systemically (skin rash, muscle, liver, gastrointestinal tract), in about 30% of marrow recipients |
Lecture 7, Slides 48, 49. Rejection is minimized by tissue matching of human leukocyte antigens (mixed lymphocyte reaction, tissue typing) and by immunosuppressive drugs: purine analogs, corticosteroids, tacrolimus and cyclosporine, and rapamycin (sirolimus). Lecture 7, Slide 51.
Not in her review, still examinable. Her review stopped at the three rejection speeds. Graft versus host disease (type IV), the four graft types, the cornea, liver and bone marrow contrast, and the immunosuppressive drugs above are still on the slides and still part of this objective.
1.6 · Objective 6 — The etiology of autoimmune conditions Know it
“Autoimmune conditions, the mechanism of the attack, we’re dealing with all of the different hypersensitivity types except one. Except one. So there are type two, three, and four for autoimmune disorders.” [part 4, 8:18–8:38] Then the causes: “You can be dealing with what’s called that sequestered antigen, like when you’re dealing with the eye. You can be dealing with a normal immune response that goes wrong, like rheumatic fever.” [part 4, 8:47–9:00] … “We talked about the non-infectious autoimmunity. You injure the one eye. You let out antigens that the body hasn’t seen before, and then it not only goes after that eye but the other eye as well.” [part 4, 9:19–9:28] … “the thymus going through senescence can initiate autoimmunity.” [part 4, 9:35]
She repeated “except one” before giving the answer, and then walked the four origins in the slide’s order.
What autoimmunity is: the immune system has lost tolerance to autoantigens and forms autoantibodies and sensitized T cells against them, destroying self tissue. It involves all hypersensitivity reactions except type I. There are genetic and gender predispositions: autoimmunities run in families, and women are more likely to have them than men. Disruption can be systemic or organ specific. Lecture 7, Slide 52.
The origins — her four, in the slide’s order
| Origin | What the slides say |
|---|---|
| Sequestered antigen | During embryonic growth some tissues are immunologically privileged; if they are damaged later, the antigens are released and attacked: the central nervous system, the lens of the eye, the thyroid, the testes Lecture 7, Slide 53. |
| A normal immune response — molecular mimicry | Similarities between foreign and self antigens result in cross-reactivity. Examples: rheumatic fever (cross-reactive streptococcal antigen); Lyme disease arthritis (Borrelia burgdorferi); reactive arthritis (Shigella, Salmonella, Campylobacter); type I diabetes (Coxsackie virus A and B, echovirus, rubella) Lecture 7, Slides 53, 54. |
| A non-infectious response | The picture: trauma to one eye releases sequestered intraocular protein antigens; they are carried to the lymph nodes and activate T cells; the effector T cells return in the bloodstream and attack the antigen in both eyes Lecture 7, Slide 55. |
| Thymus senescence | The thymus is most active in fetal development and early neonatal life, then degenerates and is replaced with fat (involution). There may be a connection to autoimmunity, though the mechanism is unclear: premature aging of the thymus is characteristic of young people with autoimmune disorders, chronic inflammation may hasten it, and decreased thymic output may mean less efficient T cell development and more opportunistic infections, cancer and autoimmunity Lecture 7, Slides 56, 57. |
Her words and the slide differ; the slide wins. She said rheumatic fever leads “to heart problems or reactive arthritis” [part 4, 9:16]. On the slides, acute rheumatic fever’s consequences are arthritis, myocarditis and late scarring of the heart valves (antibodies to streptococcal cell wall antigens cross-react with cardiac muscle) Lecture 7, Slide 58, while reactive arthritis is a separate molecular mimicry example caused by Shigella, Salmonella and Campylobacter Lecture 7, Slide 54. Keep the two names apart.
Example diseases by hypersensitivity type
| Type II (antibody against cell-surface or matrix antigens) | Type III (immune complexes) | Type IV (T cell mediated) |
|---|---|---|
| Autoimmune hemolytic anemia; autoimmune thrombocytopenic purpura; Goodpasture’s syndrome; pemphigus vulgaris and foliaceus; acute rheumatic fever; Graves’ disease (thyroid-stimulating hormone receptor → hyperthyroidism); myasthenia gravis (acetylcholine receptor → progressive weakness); insulin-resistant type 2 diabetes and hypoglycemia (insulin receptor) | Subacute bacterial endocarditis; mixed essential cryoglobulinemia; systemic lupus erythematosus (DNA, histones, ribosomes → glomerulonephritis, vasculitis, arthritis) | Type 1 diabetes (pancreatic beta-cell antigen); rheumatoid arthritis (unknown synovial joint antigen); multiple sclerosis (myelin basic protein, proteolipid protein → paralysis) |
Lecture 7, Slides 58–60. By organ: Graves’ disease (hyperthyroidism) and Hashimoto’s thyroiditis (hypothyroidism), diabetes mellitus, myasthenia gravis, and multiple sclerosis, which may be associated with an earlier Epstein–Barr or retrovirus infection. Lecture 7, Slide 61.
One deck inconsistency to know about. Rheumatoid arthritis is listed as a type III example on Slide 39 and as a type IV autoimmune disease on Slide 60. Lecture 7, Slides 39, 60. If a question hangs on it, read the stem for the mechanism it describes (immune complexes, or T cells).
1.7 · Objective 7 — Primary versus secondary immunodeficiency Know cold
“Immunodeficiencies, primary and secondary immunodeficiencies. What is a primary immunodeficiency? Well, you’re born with [it]. It’s genetic.” [part 4, 9:49–10:04] … “So what can cause a secondary immunodeficiency? HIV [human immunodeficiency virus], that’s absolutely right. Cancer, cancer chemotherapy. So … radiation, exposure to cannabis. So anything that happens after you’re born is a secondary immunodeficiency.” [part 4, 10:22–10:44]
She asked both halves of the objective as questions and took answers from the room.
In an immunodeficiency, components of the immune response are absent; deficiencies involve B and T cells, phagocytes and complement. Two general categories: Lecture 7, Slide 62.
| Primary | Secondary | |
|---|---|---|
| Definition | Congenital; usually genetic errors | Acquired after birth; caused by natural or artificial agents |
| Examples on the slides | B cell defect: agammaglobulinemia — the patient lacks antibodies; often more bacterial infections. T cell defect (thymus missing or abnormal): DiGeorge syndrome; often more fungal, protozoan, helminth and viral infections. Severe combined immunodeficiency: both limbs of the lymphocyte system missing or defective, so no adaptive immune response. Complement deficiencies; phagocyte deficiencies | Infection and organic disease; human immunodeficiency virus (T helper cells are targeted, leading to overall immune suppression); chemotherapy or radiation; blood cell cancers |
Lecture 7, Slides 62, 63, 65.
The pattern the diagram is built to show: T cell deficiency → recurrent fungal, viral and protozoan infections; B cell deficiency → recurrent bacterial infections. The same picture marks where each primary defect blocks development: some forms of severe combined immunodeficiency at the lymphoid stem cell, DiGeorge syndrome at the thymus, adenosine deaminase deficiency on the way to working T cells, and congenital agammaglobulinemia on the B cell side. Lecture 7, Slide 64.
Her words and the slide differ; the slide wins. Her list included “exposure to cannabis” [part 4, 10:37], which is not on the slide, and “cancer” in general, where the slide says blood cell cancers. Learn the slide’s list: infection, organic disease, human immunodeficiency virus, chemotherapy or radiation, blood cell cancers. Lecture 7, Slide 65. Her rule of thumb does match the slide: secondary means acquired after birth. Lecture 7, Slide 62.
1.8 · Objective 8 — The mechanisms of carcinogenesis Know it
She did not discuss this objective in the review. Her only words on cancer, “And then we talked about cancer, and we talked about different kinds of immune therapies for cancer” [part 4, 10:48–11:01], led straight into the therapies of Objective 9.
Not in her review, still examinable. This objective was skipped entirely. It is still on the exam’s objective list, and the deck answers it in seven slides.
How a cancer arises. Cancer cells appear to have genetic alterations that disrupt the normal cell division cycle. Possible causes: errors in mitosis, genetic damage, activation of oncogenes, or retroviruses. The result is new growth of abnormal cells; tumors may be benign (nonspreading, self-contained) or malignant (spreading from the tissue of origin to other sites). Immune surveillance keeps cancer “in check”. Lecture 7, Slide 66.
Transformation: a cancer arises from a single cell that has accumulated multiple mutations; oncogenes are activated by exposure to radiation, chemicals or oncogenic viruses. The slide’s diagram walks one tumor from normal epithelium through three lost tumor suppressor genes and one activated oncogene to an invasive tumor, rapid accumulation of mutations, and metastasis. Lecture 7, Slide 67.
| Oncogenic virus | Associated tumors |
|---|---|
| Papillomavirus | Genital warts (benign); carcinoma of the uterine cervix |
| Hepatitis B virus | Liver cancer (hepatocellular carcinoma) |
| Epstein–Barr virus | Burkitt’s lymphoma; nasopharyngeal carcinoma; B-cell lymphoproliferative disease |
| Human T-cell leukemia virus type 1 | Adult T-cell leukemia or lymphoma |
| Human immunodeficiency virus and human herpesvirus 8 | Kaposi’s sarcoma |
Lecture 7, Slide 68.
The necessary characteristics of cancer cells: they stimulate their own growth; ignore growth-inhibiting signals; avoid death by apoptosis; develop a blood supply (angiogenesis); leave their site of origin to invade other tissues (metastasis); replicate constantly; and evade and outrun the immune response. Lecture 7, Slide 69.
Tumor antigens. Unique antigens develop during transformation — more than 1000 identified. Tumor-specific antigens are on tumor cells but not on normal cells; tumor-associated antigens are on tumor cells and on normal cells in smaller amounts. Both provide targets for immune defense in a healthy person. Lecture 7, Slide 70.
How successful tumors evade the immune response: tumor cells can secrete TGF-β (transforming growth factor beta) to suppress the immune response and recruit regulatory T cells, which make more TGF-β and interleukin-10 and suppress the T cells specific for tumor antigens. The more regulatory T cells in a tumor, the worse the prognosis. Lecture 7, Slides 71, 72.
1.9 · Objective 9 — Immunotherapy strategies Know cold
“… we talked about different kinds of immune therapies for cancer, the immune checkpoint therapy, the adoptive cell therapy, the CAR-T [chimeric antigen receptor T] cells, the CAR-NK [chimeric antigen receptor natural killer] cells, where you’re taking cells out of the body and then you’re engineering them … putting them back to go against a tumor.” [part 4, 10:52–11:17] … “But what else do we use monoclonal antibodies for in cancer therapy? … We can link them to chemotherapeutic drugs or radionuclides. And what is the benefit of doing that?” [part 4, 11:37–11:54] … to “target just the tumor” [part 4, 12:00] … “And then we talked about different kinds of cytokine therapies like interferon.” [part 4, 12:05]
The overview slide names six strategies: immune checkpoint inhibitors, adoptive cell therapies, monoclonal antibodies, cytokine therapies, oncolytic viruses and cancer vaccines. She walked the first four and asked one question, about monoclonal antibodies. Lecture 7, Slide 73.
| Strategy | What the slides say |
|---|---|
| Immune checkpoint inhibitors | Immune checkpoints regulate the immune system and, when activated, can reduce the response to a pathogen or cancer cell. The inhibitors block checkpoint proteins from binding their partner and prevent the “off” signal, so T cells can kill cancer cells. They do not kill cancer cells directly, but help target them for other immune cells and stop the immune system turning off before the cancer is eliminated. Used for melanoma and some lung cancers Lecture 7, Slide 74. |
| Adoptive cell therapy | The patient’s cells are genetically engineered ex vivo and transferred back as therapeutic agents. Tumor-infiltrating lymphocytes (cytotoxic T cells activated and expanded) are in development, not yet approved. Chimeric antigen receptor T cells: T or natural killer cells engineered with a receptor gene specific for a cancer type; approved by the Food and Drug Administration for different blood cancers. Chimeric antigen receptor natural killer cells: the gene inserted into natural killer cells to make them more efficient killers; mostly in clinical trials, including trials on solid tumors Lecture 7, Slide 75. |
| Monoclonal antibodies | More than 100 approved for cancer diagnosis and therapy; used in diagnosis and to eliminate cancer cells, across many cancer types Lecture 7, Slide 76. |
| Cytokine therapies | Interleukin therapy: aldesleukin (interleukin-2) increases proliferation of cytotoxic T cells and natural killer cells and enhances anti-tumor antibody production; used in metastatic kidney cancer and melanoma. Interferon therapy: interferon alpha activates natural killer and dendritic cells; used in melanoma, Kaposi’s sarcoma and several blood cancers. Hematopoietic growth factors also appear: erythropoietin for red cell production, interleukin-11 for platelets Lecture 7, Slide 78. |
Her question: what is the benefit of linking a monoclonal antibody to a chemotherapy drug or a radionuclide? Her answer was to “target just the tumor”, and the slide’s two pictures show how. An antibody against CD30 (cluster of differentiation 30) is linked to the drug auristatin; it binds the lymphoma cell, is taken in and cut free inside, and the drug binds the cell’s microtubules, so the cell cannot form a mitotic spindle and dies by apoptosis. An antibody against CD20 (cluster of differentiation 20) carries a radionuclide to the malignant B cells it binds and irradiates them, damaging their DNA. In both, the antibody delivers the killing agent to the cell carrying the tumor marker. Lecture 7, Slide 77.
Not in her review, still examinable. She named four of the six strategies. The other two, and a historical one, are still on the slides.
- Coley’s toxins — immunotherapy from the 1890s: bone sarcomas were noted to regress with streptococcal skin infections, and the treatment became a mix of killed streptococci and Serratia marcescens; it fell from favor with radiation and chemotherapy. Lecture 7, Slide 79.
- Oncolytic viral therapy — the viruses attack both normal and cancer cells but have little effect on normal cells; some are naturally oncolytic (mumps), others are engineered; the challenge is that the immune system may clear them before they work; only one is approved in the United States, for melanoma. Lecture 7, Slide 80.
- Cancer vaccines — prophylactic, to prevent the infection that leads to cancer (hepatitis B against hepatocellular carcinoma; human papillomavirus against reproductive system cancers); therapeutic, to activate the immune system against tumor antigens: bacillus Calmette–Guérin, a weakened form of tuberculosis that stimulates a general immune response, used in bladder cancer; and sipuleucel-T, approved for metastatic, castration-resistant prostate cancer. Lecture 7, Slide 81.
2 · Lecture 10 — Gram-Positive Bacilli of Medical Importance
Instructional objectives — Gram Positive Bacilli of Medical Importance
- Compare and contrast the morphology, medium, laboratory tests, biochemical reactions, diseases, clinical manifestations, methods of treatment, and prevention of Gram-positive bacilli of medical importance.
- Describe the modes of transmission by which humans acquire Gram-positive bacilli of medical importance.
Appendix 2 organisms for this lecture
- Bacillus
- Clostridium
- Bacillus anthracis
- Anthrax
- Clostridium perfringens myonecrosis
- Clostridioides difficile pseudomembranous colitis
- Clostridium tetani
- Listeria monocytogenes
- Corynebacterium diphtheriae
- Propionibacterium acnes
- Tuberculosis
- Actinomyces israelii
- Nocardia
She set these objectives aside — “those learning objectives are really, really general. So let’s go to the list of organisms” [part 4, 12:24–12:31] — and went organism by organism. This section follows her order. Every organism item answers Objective 1, field by field in its table, and its transmission row answers Objective 2. Highlighted rows are the ones she brought up; the rest are what the objective still asks.
Not in her review, still examinable. Her walk gave each organism’s disease and the feature that identifies it. Objective 1 also asks for medium, laboratory tests, biochemical reactions, treatment and prevention, which she mostly did not mention, and Objective 2 asks for transmission. Both are in each table. Two list notes: Clostridium botulinum is not on the Appendix 2 list but is in the deck and she reviewed it (item 2.5); the deck also covers Bacillus cereus, Lactobacillus, Erysipelothrix rhusiopathiae and the nontuberculous mycobacteria, which are not on Appendix 2 and which she did not mention (Lecture 10, Slides 17–18, 50–51, 57–58, 90–91).
2.1 · Bacillus and Bacillus anthracis — anthrax Know cold
“Bacillus, if you recall, is our aerobic spore-forming organism. Where do we find the spore in the bacillus? In the middle, it’s centrally located.” [part 4, 12:34–12:50] … “And we talked about different forms of anthrax. Cutaneous anthrax, which is the most common. Gastrointestinal anthrax. But what’s the really bad one? Pulmonary anthrax, the [woolsorters’] disease. So that’s the one which is most deadly.” [part 4, 12:59–13:21]
Answers Objective 1 (morphology, laboratory, biochemistry, diseases, manifestations, treatment, prevention) and Objective 2 (transmission). Appendix 2: Bacillus, Bacillus anthracis, Anthrax.
| What the objective asks | What the slides say |
|---|---|
| Morphology | Genus: Gram-positive, endospore-forming, motile rods Lecture 10, Slide 7. B. anthracis: large, block-shaped rods with central spores Lecture 10, Slide 8. |
| Oxygen and biochemistry | Aerobic and catalase positive; versatile in degrading complex macromolecules; mostly saprobic, primary habitat soil; a source of antibiotics such as bacitracin Lecture 10, Slide 7. The differentiation scheme places Bacillus under “aerobic or facultative anaerobes” Lecture 10, Slide 5. |
| Disease | Anthrax, a zoonotic infection; significant for Koch’s postulates; a Category A priority pathogen, a weapon of bioterrorism (an accidental release from a Soviet bioweapon facility in 1979 had an 86% fatality rate) Lecture 10, Slide 8. |
| Virulence | A polypeptide capsule, and an exotoxin of three parts: protective antigen binds host cells and creates the receptor for the other two; edema factor impairs phagocytosis and inhibits monocyte production of tumor necrosis factor and interleukin-6; lethal factor at low levels inhibits cytokine release, and at high levels is cytolytic for macrophages, releasing large amounts of interleukin-1, tumor necrosis factor alpha and nitric oxide — a massive inflammatory response and shock cascade like septic shock Lecture 10, Slide 9. |
| Treatment and prevention | Penicillin, tetracycline or ciprofloxacin; pulmonary anthrax is also treated with antitoxin to neutralize toxins. Vaccines: live spores and toxoid for livestock; Biothrax, the only vaccine approved by the Food and Drug Administration, a purified toxoid for high-risk occupations and military personnel, not for those under 18 or over 65 Lecture 10, Slide 16. |
The forms of anthrax — her question was which is the most deadly
| Form | How it is acquired (Objective 2) | What happens |
|---|---|---|
| Cutaneous — 95% of all human cases | Through cuts or incisions in the skin; spores germinate in the tissue and grow | A painless papule that rapidly becomes an ulcer surrounded by vesicles and finally a necrotic eschar; untreated mortality about 20% Lecture 10, Slide 10. |
| Injection | Identified in heroin-injecting addicts in northern Europe; not so far identified in the United States | Like cutaneous anthrax but evident in the deep muscle where the drug was injected; can spread faster and be harder to recognize and treat Lecture 10, Slide 12. |
| Pulmonary — woolsorters’ disease | Inhalation of spores from infected animal products or soil | May have an asymptomatic latent period of two months or more. Alveolar macrophages engulf the spores and the exotoxins cause massive macrophage death. Cough, headache, fever, chills, vomiting, chest and abdominal pain, progressing to edema, capillary thrombosis and cardiovascular shock; about half have symptoms of meningitis. 99% of untreated cases die within about three days of the first symptoms — the most deadly form Lecture 10, Slide 13. |
| Gastrointestinal | Ingestion of contaminated meat | Ulceration of the mouth and esophagus with local lymphadenopathy; nausea, vomiting and malaise if the upper intestine is invaded; rapid sepsis if the large intestine is invaded. Mortality 25–60% depending on treatment Lecture 10, Slide 14. |
| Anthrax meningitis | A complication of all types | Found in up to half of all patients with pulmonary anthrax; altered mental status, headache, fever, nausea and vomiting, seizures Lecture 10, Slide 15. |
Her words and the slide differ; the slide wins. Her two superlatives match the slides exactly: cutaneous is the most common (95%), pulmonary is the most deadly. But she named three forms, and the slides have a fourth, injection anthrax Lecture 10, Slide 12, plus anthrax meningitis as a complication of all of them Lecture 10, Slide 15. A “which is not a form of anthrax” item could use either.
2.2 · Genus Clostridium — where the spore sits Know cold
“We talked about clostridium as an anaerobic spore former. Where is this spore found? … It’s not centrally located like bacillus.” [part 4, 13:26–13:41]
Answers Objective 1 (morphology, oxygen, biochemistry). Appendix 2: Clostridium.
| What the objective asks | What the slides say |
|---|---|
| Morphology | Gram-positive, spore-forming rods; oval or spherical spores, produced only under anaerobic conditions Lecture 10, Slide 19. |
| Spore position | The deck’s text gives no position for the genus. Its picture of Clostridium tetani shows a round spore at one end of the rod, swelling it Lecture 10, Slide 28; contrast the central spores of Bacillus anthracis Lecture 10, Slide 8. |
| Oxygen and biochemistry | Anaerobic and catalase negative; 120 species; synthesize organic acids, alcohols and exotoxins, the exotoxins among the most toxic substances on earth Lecture 10, Slide 19. The scheme calls them obligate anaerobes Lecture 10, Slide 5. |
| Disease | Opportunistic pathogens: wound and tissue infections, and food intoxications Lecture 10, Slide 20. |
| Bacillus | Clostridium | |
|---|---|---|
| Oxygen | Aerobic (aerobic or facultative anaerobes) | Anaerobic (obligate anaerobes) |
| Catalase | Positive | Negative |
| Spore | Central (B. anthracis) | At one end of the rod (the C. tetani picture) |
Lecture 10, Slides 5, 7, 8, 19, 28.
Why her answer is not quoted in full. The two transcripts of the recording disagree on the word she used for where the clostridial spore sits (one reads “internally”, the other “terminally”), so only the part both agree on is quoted above. The slide picture settles it.
2.3 · Clostridium perfringens — myonecrosis (gas gangrene) Know cold
“We talked about clostridium perfringens, which causes gas gangrene, the myonecrosis. And in order for that to happen, we have to have what’s called a mixed infection. What did we mean by a mixed infection? Aerobic and anaerobic. So when you get the [aerobes] in the wound, they start using up all the oxygen. And then the oxygen tension goes low enough so that those anaerobic spores can germinate.” [part 4, 13:49–14:20]
Answers Objective 1 and Objective 2. Appendix 2: Clostridium perfringens myonecrosis.
| What the objective asks | What the slides say |
|---|---|
| Disease | Myonecrosis (anaerobic cellulitis), or gas gangrene: soft tissue and wound infections, caused by C. perfringens (most common) but also C. novyi, C. septicum and other species Lecture 10, Slide 21. |
| Why it needs a mixed infection | A mixed infection: aerobic bacteria use up the oxygen to produce the low oxygen tension the organism needs (30% oxygen allows growth, 70% inhibits). 90% of contaminated wounds have the organism but only 2% develop myonecrosis — host factors decide Lecture 10, Slide 22. It is not highly invasive; it needs damaged and dead tissue and anaerobic conditions, which stimulate germination, growth and exotoxin release; fermentation of muscle carbohydrates forms gas and destroys more tissue Lecture 10, Slide 23. |
| Virulence | At least 17 toxins: alpha toxin (red cell rupture, edema, tissue destruction), theta toxin (destroys white cells), and the enzymes collagenase, hyaluronidase and DNase Lecture 10, Slide 24. — her “enzymes and substances” that break down connective tissue |
| Clinical manifestations | Anaerobic cellulitis: gas and tissue damage that stays localized. True myonecrosis: spreading tissue damage with fever, tachycardia and blackened necrotic tissue Lecture 10, Slide 26. The picture shows the rods among muscle fibers with gas-filled spaces Lecture 10, Slide 25. About 1000 cases a year in the United States; mortality 20–30% if treated, 100% if untreated Lecture 10, Slide 24. |
| Treatment and prevention | Immediate cleansing of dirty wounds, deep wounds, compound fractures and infected incisions; debridement; may require amputation; large doses of cephalosporin or penicillin; hyperbaric oxygen; no vaccine Lecture 10, Slide 27. |
| Transmission (Objective 2) | Spores are found in soil, on human skin, and in the intestine and vagina Lecture 10, Slide 21; predisposing wounds are surgical incisions, compound fractures, diabetic ulcers, septic abortions, puncture wounds and gunshot wounds Lecture 10, Slide 22. |
| Also: food poisoning | C. perfringens is the second most common form of food poisoning worldwide, a mild intestinal illness Lecture 10, Slide 33: spores in meat, fish or undercooked vegetables survive inadequate cooking and multiply (especially unrefrigerated); the toxin is made in the intestine, giving abdominal pain, diarrhea and nausea, with rapid recovery Lecture 10, Slide 41. |
2.4 · Clostridium tetani — tetanus Know it
“We talked about clostridium [tetani] also needing that mixed infection to use up that oxygen.” [part 4, 14:42–14:45]
Answers Objective 1 and Objective 2. Appendix 2: Clostridium tetani.
| What the objective asks | What the slides say |
|---|---|
| Morphology | The slide’s picture shows rods with a round spore at one end Lecture 10, Slide 28. |
| Disease | Tetanus, or lockjaw, a neuromuscular disease. Most common among geriatric patients and intravenous drug users, and in neonates in developing countries Lecture 10, Slide 28; neonatal tetanus is pictured Lecture 10, Slide 31. |
| Oxygen | Strict anaerobe — low oxygen tension is needed to germinate the spores and produce toxin Lecture 10, Slide 29. |
| Mechanism | Tetanospasmin, a neurotoxin, binds motor nerve endings and blocks the release of gamma-aminobutyric acid and glycine, the transmitters that inhibit muscular contraction, so muscles contract uncontrollably. The toxin goes to the spinal neuron and blocks its regulatory function Lecture 10, Slides 29, 30. |
| Clinical manifestations | Incubation 4–10 days, and the shorter, the more serious. Death is most often from paralysis of the respiratory muscles; mortality 10–70% depending on delayed attention, short incubation and head wounds Lecture 10, Slide 29. |
| Treatment and prevention | Aimed at the degree of toxemia and infection, and at maintaining homeostasis. Antitoxin (human tetanus immune globulin) inactivates circulating toxin but does not counteract toxin already bound. Penicillin or tetracycline, and muscle relaxants. Vaccine available; booster every 10 years Lecture 10, Slide 32. |
| Transmission (Objective 2) | A common resident of soil and the gastrointestinal tracts of animals Lecture 10, Slide 28; spores usually enter through accidental puncture wounds, burns, umbilical stumps, frostbite and crushed body parts Lecture 10, Slide 29. |
Her words and the slide differ; the slide wins. She said C. tetani also needs “that mixed infection”. The tetanus slides do not say so: they call it a strict anaerobe that needs low oxygen tension and list the wounds the spores enter Lecture 10, Slide 29. “Mixed infection” is the deck’s term for myonecrosis only Lecture 10, Slide 22. If an answer choice offers “mixed infection” for tetanus, the slide does not back it.
Two contrasts the slides set up and an exam can use. Tetanus versus botulism: tetanospasmin blocks the inhibitory transmitters, so muscles contract uncontrollably Lecture 10, Slide 29; botulin blocks acetylcholine, so the paralysis is flaccid Lecture 10, Slides 35, 38. Antitoxin works on circulating toxin, not toxin already bound, both here and in diphtheria Lecture 10, Slides 32, 64.
2.5 · Clostridium botulinum — botulism Know cold
“We talked about clostridium botulinum, botulism. When you have improperly home-canned foods or you are feeding babies improperly made foods or honey, because remember honey has the spores in it. And what do you get when a baby gets those spores? Floppy baby syndrome, yes. That’s why you don’t feed little ones honey.” [part 4, 14:54–15:24]
Answers Objective 1 and Objective 2. Not on the Appendix 2 list, but it is in the deck (Slides 33–40) and she reviewed it, so treat it as examinable.
| What the objective asks | What the slides say |
|---|---|
| Organism | A spore-forming anaerobe that commonly inhabits soil and water Lecture 10, Slide 34. |
| Disease | Botulism, an intoxication associated with inadequate food preservation; rare but severe, usually from home-canned food Lecture 10, Slides 33, 34. |
| Mechanism | Spores are on food when it is gathered and processed; if reliable temperature and pressure are not reached, the air is evacuated but the spores remain, and the anaerobic conditions favor germination and growth. The toxin, botulin, is carried to neuromuscular junctions and blocks the release of acetylcholine, which muscle contraction needs Lecture 10, Slide 35. |
| Clinical manifestations | Double or blurred vision, difficulty swallowing, dizziness; sometimes nausea and vomiting; descending muscular paralysis; respiratory compromise. Mortality has fallen to about 10% because of ventilators Lecture 10, Slide 37. |
| Infant botulism | Ingested spores germinate and release toxin: flaccid paralysis, “floppy baby syndrome”, which may be associated with honey or homemade baby food; up to 80% of botulism cases each year Lecture 10, Slide 38. Of 273 cases reported in a 2021 national survey, 66% were infant, 24% wound and 8% food-borne Lecture 10, Slide 39. |
| Other forms | Wound botulism: spores enter a wound (intravenous drug users, often black tar heroin) Lecture 10, Slide 38. Iatrogenic: cosmetic or therapeutic botulinum toxin causing systemic intoxication. Intestinal colonization in a person over 1 year old Lecture 10, Slide 39. |
| Laboratory, treatment, prevention | Determine the presence of toxin in food, intestinal contents or feces. Antitoxin, with cardiac and respiratory support; infectious botulism is treated with penicillin. Prevention: proper preserving and handling of canned foods; preservatives (sodium nitrite, salt, vinegar); discard bulging cans; boil home-bottled foods for at least 10 minutes Lecture 10, Slide 40. |
| Transmission (Objective 2) | Food-borne: preformed toxin in poorly preserved food (low-acid home-canned foods such as green beans and corn, but also meats, fish and dairy; rarely commercial foods) Lecture 10, Slide 34. Infant: ingested spores. Wound: spores in a wound Lecture 10, Slide 38. |
The distinction her honey example turns on: food-borne botulism is poisoning by toxin already made in the food Lecture 10, Slides 33, 35, whereas infant botulism is spores that germinate in the baby and make the toxin there Lecture 10, Slide 38.
2.6 · Clostridioides difficile — pseudomembranous colitis Know cold
“And individuals who are likely to have problems with C. diff [Clostridioides difficile] are who? People with long-term antibiotics, which is going to wipe out the normal flora. And then you might, and if it’s a mild case, you just cut back on the antibiotics and use fluid therapy. But you may have to go to more extensive measures if it’s a more severe case. And what is a fun alternative therapy for that?” [part 4, 15:37–16:02] … “the fecal transplant” [part 4, 16:06]
Answers Objective 1 and Objective 2. Appendix 2: Clostridioides difficile pseudomembranous colitis.
| What the objective asks | What the slides say |
|---|---|
| Classification | Formerly classified as Clostridium; differentiated by RNA sequencing Lecture 10, Slide 42. |
| Who gets it, and why | A normal resident of the colon in low numbers, relatively noninvasive: treatment with broad-spectrum antibiotics kills the other bacteria, allowing it to overgrow; its enterotoxins damage the intestine Lecture 10, Slide 42. 70% of cases had used antibiotics in the prior 12 weeks Lecture 10, Slide 44. Populations at risk: antibiotic exposure, gastrointestinal surgery or manipulation, long stays in healthcare settings, serious underlying illness, immunocompromising conditions, advanced age, gastric acid inhibitors, and consumption of trehalose sugar Lecture 10, Slide 45. |
| Disease | Antibiotic-associated (pseudomembranous) colitis, toxic megacolon, perforation of the colon; a major cause of diarrhea in hospitals and increasingly of community-acquired diarrhea; a strain found in 2005 makes 20 times the exotoxin; named one of the top three antibiotic-related threats Lecture 10, Slide 43. |
| Clinical manifestations | Watery diarrhea, fever, loss of appetite, nausea, abdominal pain and tenderness; necrosis of the intestinal wall, which sloughs off as the pseudomembrane; perforation of the wall Lecture 10, Slide 46. |
| Treatment | Mild, uncomplicated cases: fluid and electrolyte replacement and withdrawal of antimicrobials. Severe infections: oral vancomycin or metronidazole. Fecal microbiota transplant: donor cultures by colonoscope or nasogastric tube, as much as 90% effective, or “poop pills” — a donor sample centrifuged into pellets and taken as capsules Lecture 10, Slide 48. |
| Prevention and transmission (Objective 2) | Increased precautions to prevent spread Lecture 10, Slide 48; the organism is already a colon resident and the disease follows disruption of the flora Lecture 10, Slide 42. |
Her words and the slide differ; the slide wins. A small one. She said “long-term antibiotics”; the slide’s mechanism is broad-spectrum antibiotics killing the competing flora Lecture 10, Slide 42, and antibiotic exposure is one of eight risk groups, alongside gastric acid inhibitors, advanced age and the rest Lecture 10, Slide 45.
2.7 · Listeria monocytogenes — listeriosis Know cold
“Then we had listeria monocytogenes. … this one is a tough one to deal with because tough to grow because it requires what in order to grow. … This is the one that needs cold. This is the one that can grow in your refrigerator and it needs cold enrichment in order to grow. … A lot of dairy.” [part 4, 16:15–16:57]
Answers Objective 1 and Objective 2. Appendix 2: Listeria monocytogenes.
| What the objective asks | What the slides say |
|---|---|
| Morphology | A regular non-spore-forming Gram-positive bacillus (stains uniformly, not pleomorphic) Lecture 10, Slide 50; ranges from coccobacilli to long filaments; 1–4 flagella; no capsules Lecture 10, Slide 53. |
| Hardiness | Resistant to cold, heat, salt, pH extremes and bile Lecture 10, Slide 53; can contaminate foods and grow during refrigeration Lecture 10, Slide 55. |
| Virulence | Replicates in the cytoplasm of cells after inducing phagocytosis, which lets it avoid the humoral immune system Lecture 10, Slide 53; its multiplication cycle is pictured Lecture 10, Slide 54. |
| Disease and manifestations | Listeriosis: often mild or subclinical in normal adults (fever, diarrhea, sore throat); in immunocompromised patients, fetuses and neonates it affects the brain and meninges, with 20% fetal loss and a 3% death rate in newborns Lecture 10, Slide 55. |
| Laboratory | Culture requires a lengthy cold enrichment process; rapid diagnostic tests use ELISA (enzyme-linked immunosorbent assay), immunofluorescence and DNA analysis Lecture 10, Slide 56. |
| Treatment and prevention | Ampicillin and trimethoprim/sulfamethoxazole, erythromycin. Prevention: pasteurization and cooking Lecture 10, Slide 56. |
| Transmission (Objective 2) | Primary reservoir soil and water, and animal intestines. Most cases are associated with dairy products, poultry and meat (found in 12% of ground beef and 15% of chicken tested); the most recent outbreak was dairy Lecture 10, Slide 55; recent recalls include soft cheeses and precooked pasta meals Lecture 10, Slide 52. |
Her words and the slide differ; the slide wins. She said Listeria “needs cold” and “needs cold enrichment in order to grow”. The slides say something narrower: it is resistant to cold (and to heat, salt, pH extremes and bile) Lecture 10, Slide 53 and can grow during refrigeration Lecture 10, Slide 55; the cold enrichment is how the laboratory cultures it Lecture 10, Slide 56. Nothing on a slide says it requires cold. What follows for an exam: refrigeration does not stop it, so prevention is pasteurization and cooking Lecture 10, Slide 56, and an answer choice saying it “requires cold to grow” goes beyond the slides.
2.8 · Corynebacterium diphtheriae — diphtheria Know cold
“Then we had [Corynebacterium] diphtheria. This is one that we’re seeing more of because people are not vaccinating. And how do you diagnose diphtheria? … What is characteristic for diphtheria? The pseudomembrane, the pseudomembrane. And you may have to use antitoxin which gets rid of the toxin that’s free in the body …” [part 4, 16:59–17:33]
Answers Objective 1 and Objective 2. Appendix 2: Corynebacterium diphtheriae.
| What the objective asks | What the slides say |
|---|---|
| Morphology and group | An irregular non-spore-forming Gram-positive bacillus: pleomorphic, stains unevenly; the irregular group all produce catalase and have mycolic acids and a unique peptidoglycan in the wall Lecture 10, Slide 59. The scheme calls it non-acid-fast Lecture 10, Slide 5. |
| Epidemiology | A reservoir of healthy carriers, so the potential is always present, but respiratory diphtheria in the United States is rare; most cases occur in non-immunized children in crowded, unsanitary conditions. Respiratory (pharyngeal, tonsillar, laryngeal, nasal) or cutaneous (most common in the tropics) Lecture 10, Slide 61. |
| Disease and manifestations | Two stages. Local infection: upper respiratory inflammation, sore throat, nausea, vomiting, swollen lymph nodes, and the pseudomembrane — formed by solidification of inflammatory fluids — which can cause asphyxiation. Diphtherotoxin and toxemia: the heart (myocarditis and an abnormal electrocardiogram) and the nerves (weakness and paralysis) Lecture 10, Slide 62. |
| Laboratory and diagnosis | The pseudomembrane and swelling are indicative; alkaline methylene blue stain; conditions and history; serological assay Lecture 10, Slide 63. |
| Treatment | Antitoxin, in horse serum since the 1890s, not typically given in non-respiratory cases; it does not neutralize bound toxin, but does neutralize circulating toxin to prevent spread. Penicillin or erythromycin Lecture 10, Slide 64. |
| Prevention | Toxoid vaccine series and boosters, in infancy, at 15 months and at school age Lecture 10, Slide 64. |
| Transmission (Objective 2) | Respiratory droplets from carriers or actively infected people Lecture 10, Slide 61. |
Her aside, not on a slide. Her opening, “we’re seeing more of because people are not vaccinating”, is not on a slide. What the slide says is that respiratory diphtheria is rare in the United States and that most cases occur in non-immunized children Lecture 10, Slide 61. Her antitoxin point matches the slide: it acts on the free, circulating toxin, not toxin already bound Lecture 10, Slide 64.
2.9 · Cutibacterium (Propionibacterium) acnes Know it
“Then we have the cutibacterium, also called [Propionibacterium] acnes. This is one that we thought was just associated with acne but we now know that it can also be very serious because it has been implicated in a lot of infections associated with implants and shunts. So it’s something that we worry about more now than we used to.” [part 4, 17:39–18:04]
Answers Objective 1 and Objective 2. Appendix 2: Propionibacterium acnes (now Cutibacterium).
| What the objective asks | What the slides say |
|---|---|
| Morphology and oxygen | Gram-positive rods; aerotolerant or anaerobic; slow growing, more than 6 days; nontoxigenic Lecture 10, Slide 65. |
| Disease | A common resident of the pilosebaceous glands that causes acne through inflammatory mediators Lecture 10, Slide 65; more recently implicated in chronic invasive, implant, endovascular and central nervous system shunt infections Lecture 10, Slide 66. |
| Why it is hard | It forms a biofilm on prosthetics, which increases its tolerance to antibiotics and immune defense; it is difficult to diagnose because it grows so slowly, so prolonged incubation under strict anaerobic conditions is needed Lecture 10, Slide 66. |
| Treatment | Hardware may need to be removed and the area aggressively debrided; prolonged courses of antibiotics, often months, including weeks of an intravenous beta-lactam Lecture 10, Slide 66. |
| Transmission (Objective 2) | The slides give no route beyond its home on the skin, in the pilosebaceous glands Lecture 10, Slide 65. |
2.10 · Mycobacterium tuberculosis — the stages of tuberculosis Know it
“Mycobacterium, the acid fast organisms. Mycobacterium tuberculosis. We’ve talked about the different stages of tuberculosis. Go review your stages of tuberculosis.” [part 4, 18:06–18:17]
Answers Objective 1 and Objective 2. Appendix 2: Tuberculosis.
“Go review” is a direct instruction, but she did not put it to the room as a question, so by this page’s rule it is Know it — weight it at the top of that tier. The stages are the answer she pointed at.
| Stage | What the slides say |
|---|---|
| Course of infection | 5–10% of infected people develop clinical disease. Inactive tuberculosis is not contagious, can be detected by a blood or skin test, and may activate at any time. Untreated, the disease progresses slowly, and most cases are contained in the lungs. Clinical tuberculosis divides into primary, secondary (reactivation or reinfection), and disseminated (extrapulmonary) Lecture 10, Slide 72. |
| Primary | Infectious dose 10 cells. Phagocytosed by alveolar macrophages, it multiplies inside them. After 3–4 weeks the immune system attacks, forming tubercles: granulomas of a central core of bacilli surrounded by white cells. If the center breaks down into necrotic caseous lesions, they gradually heal by calcification. Stimulates a cell-mediated response Lecture 10, Slide 73. |
| Secondary (reactivation or reinfection) | If the patient does not recover from primary tuberculosis, the bacilli can reactivate; tubercles expand and drain into the bronchial tubes and upper respiratory tract. Violent coughing, greenish or bloody sputum, fever, anorexia, weight loss and fatigue (“consumption”); untreated, 60% mortality Lecture 10, Slide 74. |
| Extrapulmonary (disseminated) | During secondary tuberculosis the bacilli disseminate to the regional lymph nodes, kidneys, long bones, genital tract, brain and meninges; tuberculosis of the meninges carries 30–50% mortality even when treated Lecture 10, Slide 75. |
| What the objective asks | What the slides say |
|---|---|
| Genus | Gram-positive irregular bacilli; acid-fast; mycolic acids and waxes in the wall; strict aerobes; produce catalase; no capsules, flagella or spores; grow slowly. Nontuberculous mycobacteria are a problem in immunosuppressed patients Lecture 10, Slide 67. |
| Virulence | The tubercle bacillus makes no exotoxins or enzymes that contribute to infectiousness; its complex waxes and cord factor prevent destruction by lysosomes or macrophages Lecture 10, Slide 70. |
| Epidemiology | Predisposing factors: inadequate nutrition, a debilitated immune system, poor access to care, lung damage, genetics. An estimated one third of the world and 15 million in the United States carry it; the highest United States rate is in recent immigrants Lecture 10, Slide 71. |
| Laboratory and diagnosis | Mantoux test: intradermal purified protein derivative, read for a red wheal (induration) at 48–72 hours. QuantiFERON-TB Gold: blood incubated with mycobacterial proteins, measuring the release of gamma interferon. False positives from the bacillus Calmette–Guérin vaccine or other Mycobacterium species; false negatives too early in infection or in immunosuppressed patients Lecture 10, Slide 76. Acid-fast staining of sputum (Ziehl–Neelsen, fluorescent), culture, DNA probes Lecture 10, Slide 77. |
| Treatment and prevention | 6–24 months of at least two drugs from isoniazid, rifampin, ethambutol, streptomycin, pyrazinamide, thioacetazone and para-aminosalicylic acid; a one-pill combination of isoniazid, rifampin and pyrazinamide. A vaccine from the attenuated Calmette–Guérin strain of M. bovis is used in other countries. Preventive treatment for those at risk or possibly latent: 9 months of isoniazid or 4 months of rifampin Lecture 10, Slide 79. |
| Transmission (Objective 2) | Airborne respiratory droplets; the bacillus is very resistant Lecture 10, Slide 71. |
2.11 · Mycobacterium leprae — leprosy Know cold
“And then mycobacterium leprae, that’s your armadillos. … And remember it comes in two different forms, the tuberculoid form which is a little less serious and then the lepromatous which … the major disfiguration” [part 4, 18:24–18:36] … “in areas where we do not have a lot of healthcare … diagnose the leprosy … The feather test” [part 4, 18:43–18:53]
Answers Objective 1 and Objective 2. Appendix 2 lists Tuberculosis; M. leprae is on the deck’s own organism list (Slide 3).
| What the objective asks | What the slides say |
|---|---|
| Organism | Hansen’s bacillus (Hansen’s disease). A strict parasite that has not been grown on artificial media or tissue culture — it is grown in armadillos. The slowest growing of all species; multiplies within host cells in large packets called globi Lecture 10, Slide 80. |
| Disease | Leprosy, a chronic disease that begins in the skin and mucous membranes and progresses into the nerves Lecture 10, Slide 80. Macrophages phagocytize the bacilli, but a weakened macrophage or slow T cell response may not kill them; incubation 2–5 years; untreated, the bacilli grow slowly in skin macrophages and the Schwann cells of peripheral nerves Lecture 10, Slide 83. |
| The two forms | Tuberculoid: asymmetrical, shallow lesions that damage nerves, giving local loss of pain reception. Lepromatous: a deeply nodular infection causing severe disfigurement of the face and extremities, with widespread dissemination Lecture 10, Slide 83. Which form develops seems to depend on the T helper response: T helper 1 favors tuberculoid, T helper 2 favors lepromatous Lecture 10, Slide 84; both are pictured Lecture 10, Slides 85, 86. |
| Diagnosis | Symptoms, microscopic examination of lesions and history: numbness in the hands and feet, loss of heat and cold sensitivity, muscle weakness, thickened earlobes, chronic stuffy nose; acid-fast bacilli in skin lesions, nasal discharges and tissue samples Lecture 10, Slide 87. The feather test is named and pictured: a feather touched to the skin Lecture 10, Slide 88, which checks for the lost sensation on Slides 83 and 87 |
| Treatment and prevention | Long-term combined therapy: tuberculoid, rifampin and dapsone for 6 months; lepromatous, rifampin, dapsone and clofazimine for up to 2 years, then dapsone. Prevention needs constant surveillance of high-risk populations; the bacillus Calmette–Guérin vaccine has limited efficacy, and a defined subunit vaccine is in trials Lecture 10, Slide 89. |
| Transmission (Objective 2) | The mechanism of transmission is not fully verified; there is a possibility of zoonotic transmission from armadillos. Not highly virulent; health and living conditions influence susceptibility. Most Florida cases are in Central Florida, along the Interstate 4 corridor Lecture 10, Slide 82. |
Her words and the slide differ; the slide wins. Her shorthand “that’s your armadillos” is true in two narrower senses on the slides: armadillos are where it is grown, since it will not grow on artificial media Lecture 10, Slide 80, and zoonotic transmission from armadillos is a possibility, with the mechanism of transmission not fully verified Lecture 10, Slide 82. Her ranking of the forms (tuberculoid less serious) fits the slide’s descriptions, though the slide does not rank them.
Her aside, not on a slide. The setting she gave for the feather test, areas without much healthcare, is not on the slide; Slide 88 names the test and pictures it.
2.12 · Actinomyces israelii — actinomycosis Know it
“And then we talked about actinomyces israelii and this is one that is normally harmless in the [oral] cavity but if you happen to get exposed to it through a penetrating wound where it’s not supposed to be, then you could be dealing with much more serious problems. If it gets in the gut, … cause appendicitis …” [part 4, 18:56–19:26]
Answers Objective 1 and Objective 2. Appendix 2: Actinomyces israelii.
| What the objective asks | What the slides say |
|---|---|
| Morphology | Actinomycetes: Actinomyces and Nocardia are nonmotile filamentous bacteria related to the mycobacteria that may cause chronic infection of skin and soft tissue Lecture 10, Slide 92; the scheme lists them as filamentous, branching cells Lecture 10, Slide 5. |
| Disease | A normally harmless resident of the oral cavity, digestive tract and genital tract that can cause chronic, hard-to-diagnose infections if it gains access to deeper tissues Lecture 10, Slide 93. |
| Clinical manifestations | Cervicofacial disease, a complication of oral infection; thoracic actinomycosis, a necrotizing lung disorder; abdominal actinomycosis, a complication of a burst appendix, gunshot wounds or ulcers; uterine actinomycosis, a complication of intrauterine devices. Actinomyces viscosus causes dental caries and is associated with some endocarditis Lecture 10, Slide 93. |
| Treatment | Surgically, and with penicillin, erythromycin or sulfonamides Lecture 10, Slide 93. |
| Transmission (Objective 2) | From the body’s own flora, when the organism reaches deeper tissue Lecture 10, Slide 93. |
Her words and the slide differ; the slide wins. Her direction is reversed. She said that if it gets into the gut it can cause appendicitis; the slide lists abdominal actinomycosis as a complication of a burst appendix (and of gunshot wounds and ulcers) Lecture 10, Slide 93. The burst appendix is how a normally harmless resident reaches deeper tissue, not a disease the organism causes.
2.13 · Nocardia — nocardiosis Know it
She did not mention Nocardia in the review. It is the last organism on the Appendix 2 list and the last slide of the deck, and her walk ended at Actinomyces.
Answers Objective 1. Appendix 2: Nocardia.
Not in her review, still examinable. An Appendix 2 organism her walk left out. Two slides cover it.
| What the objective asks | What the slides say |
|---|---|
| Morphology | A nonmotile filamentous bacterium related to the mycobacteria Lecture 10, Slide 92. |
| Disease and manifestations | Pulmonary, cutaneous or subcutaneous infections. Nocardia brasiliensis causes a pulmonary disease similar to tuberculosis, whose lesions may extend through the chest wall and disseminate to the brain and kidneys. Also involved in mycetoma, a granulomatous inflammatory response in the deep dermis and subcutaneous tissue Lecture 10, Slide 94. |
| Treatment | Often treated with cephalosporins Lecture 10, Slide 94. |
| Transmission (Objective 2) | No route is given on the slides Lecture 10, Slide 94. |
2.14 · Objective 2 — How humans acquire them Know it
She did not take this objective on its own. Some routes came up inside her organism walk: wounds for gas gangrene, home-canned food and honey for botulism, food in the refrigerator for Listeria, and a penetrating wound for Actinomyces.
Not in her review, still examinable. Objective 2 stands on its own on the syllabus, and her organism walk only touched it. Here it is in one place, from the slides.
| Organism | How humans acquire it |
|---|---|
| Bacillus anthracis | A zoonosis Lecture 10, Slide 8: spores through cuts or incisions (cutaneous) Lecture 10, Slide 10; injected heroin (injection) Lecture 10, Slide 12; inhaled spores from infected animal products or soil (pulmonary) Lecture 10, Slide 13; contaminated meat (gastrointestinal) Lecture 10, Slide 14. |
| Clostridium perfringens | Spores from soil, skin, intestine or vagina in a wound Lecture 10, Slides 21, 22; spores surviving undercooking in food Lecture 10, Slide 41. |
| Clostridium tetani | Spores from soil or animal gastrointestinal tracts entering puncture wounds, burns, umbilical stumps, frostbite or crushed body parts Lecture 10, Slides 28, 29. |
| Clostridium botulinum | Preformed toxin in poorly preserved food; ingested spores (infants: honey, homemade baby food); spores in a wound Lecture 10, Slides 34, 38. |
| Clostridioides difficile | Already a colon resident; disease follows broad-spectrum antibiotics; precautions against spread Lecture 10, Slides 42, 48. |
| Listeria monocytogenes | Soil, water and animal intestines; contaminated food that grows during refrigeration — dairy, poultry, meat Lecture 10, Slide 55. |
| Corynebacterium diphtheriae | Respiratory droplets from carriers or actively infected people Lecture 10, Slide 61. |
| Cutibacterium acnes | A skin resident (pilosebaceous glands); no route given Lecture 10, Slide 65. |
| Mycobacterium tuberculosis | Airborne respiratory droplets Lecture 10, Slide 71. |
| Mycobacterium leprae | Not fully verified; possibly zoonotic from armadillos Lecture 10, Slide 82. |
| Actinomyces israelii | The body’s own flora reaching deeper tissue Lecture 10, Slide 93. |
| Nocardia | No route given Lecture 10, Slide 94. |
3 · Lecture 12 — Epidemiology
Instructional objectives — Epidemiology
- Distinguish between descriptive and analytic epidemiology.
- Describe the specific uses for epidemiology training.
- Describe key events in the history and development of epidemiology, including genomic epidemiology
- Identify common sources of epidemiologic data.
- Define the primary components of public health surveillance.
- Define reportable disease
- Describe selected measures of morbidity and mortality.
- Distinguish between the terms association and causation.
- Define the terms endemic, epidemic, pandemic, sporadic, and herd immunity.
- Compare and contrast applications of epidemiology, including policy development, outbreak investigation, social and behavioral issues, the environment and occupational health
She had given this lecture that morning, so the review gave it under a minute: a list [part 4, 19:38–20:23] that follows the objectives in order but skips Objectives 2, 4 and 6. During the lecture she had flagged things directly — what to know, and what not to memorize — and those are quoted in the boxes marked In the lecture, with their part of the recording. One item per objective follows.
3.1 · Objective 1 — Descriptive versus analytic epidemiology Know cold
“So you need to know that difference between descriptive and analytic, those different factors.” [part 4, 19:38–19:41]
“you need to know the basic components of descriptive epidemiology versus analytic epidemiology.” [part 2, 6:51]
The one Lecture 12 item she said “need to know” about twice, once in the lecture and once in the review. “The basic components” are the two triads.
| Descriptive epidemiology | Analytic epidemiology | |
|---|---|---|
| What it does | Examines the distribution of a disease in a population and its basic features in terms of time, place and person; formulates hypotheses and examines associations | Tests a specific hypothesis about the relationship of a disease to a specific cause, relating the exposure of interest to the outcome of interest; a cause-effect relationship |
| Typical designs | Community health survey (also called cross-sectional or descriptive studies) | Cohort, case-control, experimental |
| Its triad | Person, place, time Lecture 12, Slide 33. | Host, environment, agent Lecture 12, Slide 37. |
Lecture 12, Slide 32. Before any analytic study, the descriptive components have to be understood first. Lecture 12, Slide 33.
The components
- Person — age, gender, socioeconomic status (education, occupation, income), marital status, ethnicity, race or genetic profile, behavior and habits. Lecture 12, Slide 34.
- Place — geographically restricted or widespread (outbreak, epidemic, pandemic); climate effects; urban, suburban or rural; relation to environmental exposure (water, food supply); one cluster or several. Lecture 12, Slide 35.
- Time — changing or stable; clustered (epidemic) or evenly distributed (endemic); time trends: point source (localized and stationary), propagated (spreading, may be extended), seasonal, and secular (over a prolonged period, usually years). Lecture 12, Slide 36.
- Agent — biological (microorganisms), physical (temperature, radiation, trauma), chemical (acids, alkalis, poisons, tobacco), environmental (nutrients, allergens), psychological experiences. Lecture 12, Slide 38.
- Host — genetic endowment, immunologic status, personal characteristics, personal behavior, and definitive versus intermediate host in vector-borne disease. Lecture 12, Slide 39.
- Environment — living conditions (housing, crowding, water supply, refuse, sewage), atmosphere and climate, and the modes of communication that bring host and agent together: vector, vehicle, reservoir. Lecture 12, Slide 40.
The worked example: John Snow and cholera
Descriptive: during the Golden Square outbreak in London he marked where cholera cases lived and worked on a map (now called a spot map) along with the water pumps, found more cases near Pump A, questioned residents about their pump, noted few cases near a brewery with its own deep well, and found the common factor was Pump A; the pump was closed and the outbreak ended. Lecture 12, Slide 41. Analytic: re-examining data from different outbreaks, he found the highest death rates in districts served by the Lambeth and Southwark/Vauxhall companies, both drawing water downstream of London; after Lambeth moved its intake upstream in 1852 he hypothesized that water from below London was the source, and tested it by identifying the water source of every house with a cholera death. Without any knowledge of microbes — Koch’s postulates came in 1884 — he established that water could transmit cholera. Lecture 12, Slide 42.
3.2 · Objective 2 — The uses of epidemiology training Know it
She did not mention this objective in the review; her closing list went from descriptive versus analytic straight to history.
Not in her review, still examinable. Still an objective, answered by two slides. Lecture 12, Slides 7, 8.
What epidemiology is: epi (upon), demos (people), ology (science) — the science of what falls upon people, a bridge between the biomedical, social and behavioral sciences Lecture 12, Slide 4; the study of the occurrence and distribution of health-related diseases or events in specified populations, of their determinants, and the application of that knowledge to control the problem. The five W’s frame every study: what (the health event or diagnosis), who, where, when, and why (causes, risk factors, modes of transmission). Lecture 12, Slide 5.
| Use of epidemiology training | What it involves |
|---|---|
| Outbreak response | Identifying, reporting and investigating outbreaks in a timely manner |
| Public health surveillance | Setting up, managing and evaluating surveillance systems |
| Public health communication | Developing and delivering public health communications |
| Disease prioritization | Evaluating and prioritizing diseases of concern, including the clinical picture: who gets the disease, who dies from it, what the outcome is |
| Training and mentoring | Of health professionals |
| Experimental epidemiology | Developing a hypothesis for a health concern and designing an experimental model to test it |
| Program evaluation and management | Evaluating prevention and intervention programs, such as vaccine and clinical trials, and managing their staff and resources |
Lecture 12, Slides 7, 8. Its impacts reach public health (disease prevention), clinical medicine (classification and diagnosis), pathophysiology (biological mechanisms), biostatistics (quantifying disease frequency) and the social sciences (social context). Lecture 12, Slide 6.
3.3 · Objective 3 — History, including genomic epidemiology Know cold
“Go back and look at the history and the people who are important in history that I mentioned a few times.” [part 4, 19:45–19:49]
“You need to know genomic epidemiology.” [part 3, 24:46]
Two halves with two weights. The history is a “go back and look”; genomic epidemiology is a “need to know” from the lecture, which is what puts the item in Know cold.
| Who or when | What for |
|---|---|
| Hippocrates, 400 BC | Attempted to explain disease from a rational rather than spiritual standpoint — environmental and host factors |
| John Graunt, 17th century | Pioneered tabulating population health and mortality in rates, ratios and proportions; noted disparities between males and females, high infant mortality, urban and rural differences, and seasonal variation |
| William Farr, 1800s | Systematically collected and analyzed Britain’s mortality statistics; the father of modern vital statistics; developed life tables; reported to the authorities and the public |
| John Snow, mid-1800s | An anesthesiologist who used epidemiologic approaches on the London cholera epidemic; the father of field epidemiology; his studies show the method still used: descriptive and analytic epidemiology |
| Mid to late 1800s; 1930s–1940s | A focus on acute infectious diseases; then methods extended to noninfectious diseases, with research methods developing after World War II |
| Doll and Hill, 1950 | Smoking and lung cancer |
| Framingham Heart Study, from 1948 | A multigenerational study of the common factors contributing to cardiovascular disease |
| 1960s–1970s; 1980s | Epidemiological methods used to eradicate smallpox worldwide; then extended to injuries and violence |
| 1990s, accelerating after 2001 | Deliberate spread of disease: biological warfare and bioterrorism |
| Continuing | New infectious agents (Ebola virus, human immunodeficiency virus, severe acute respiratory syndrome, COVID) and changed ones (drug-resistant tuberculosis, influenza variants) |
Lecture 12, Slides 9–12. The person the deck comes back to most is John Snow, three times Lecture 12, Slides 11, 41, 42.
Genomic epidemiology, in her words in the lecture “the really best tool we have now” [part 3, 24:00]. The deck calls its advent one of the most important developments in epidemiology and one of the most reliable tools in outbreak investigation Lecture 12, Slide 12. What it is: monitoring the genetic makeup of pathogens, made possible by advances in sequencing. Its applications to public health:
- Early outbreak detection and investigation — if the pathogens in different cases are closely related, they may be part of the same outbreak;
- Identify transmission links — a common pathway of spread;
- Identify or confirm sources of exposure;
- Link cases or outbreaks in different locations, by understanding disease location and spatial distribution.
Applying this information can help control health problems. Lecture 12, Slide 69.
The Slide 13 graph Light touch
“This particular graph, which I’m not asking you to memorize, looks at genetic susceptibility to cancer over a lifespan” [part 1, 11:25]
The slide’s point is the sentence, not the curve: epidemiological studies can impact personal health, through data on what affects long-term health, as well as public health. Lecture 12, Slide 13.
3.4 · Objective 4 — Common sources of epidemiologic data Know it
She did not mention this objective in the review.
Not in her review, still examinable. One table answers it. Lecture 12, Slide 18.
| Source | Method | Example |
|---|---|---|
| Individual persons | Questionnaire, survey | A food-borne illness outbreak; the National Health and Nutrition Examination Survey of the CDC (Centers for Disease Control and Prevention), health data on United States residents |
| Environment | Samples from the environment (river water, soil); sensors for environmental change | Water from area streams checked for chemical pollutants; air-quality ratings |
| Health care providers | Notifications to the health department when cases of certain diseases are seen | Reporting cases of meningitis |
| Nonhealth-related sources (financial, legal) | Sales records, court records | Cigarette sales; intoxicated driver arrests |
Lecture 12, Slide 18. Social media can also be a valuable source for monitoring disease outbreaks and mental health issues. Lecture 12, Slide 20.
3.5 · Objective 5 — Public health surveillance Know it
“Public health surveillance, the different kinds of surveillances that we talked about.” [part 4, 19:52–19:54]
She named the kinds of surveillance specifically, so the table of kinds is the part to have firm.
What it is: a tool that systematically collects, analyzes and interprets data to facilitate the prevention and control of disease. It measures what is going on in the population, the need for interventions, and their effects, and informs decisions; how it is done may differ between developed and developing nations. Lecture 12, Slide 14.
The critical characteristics, once there is a clear objective for how data will be collected, consolidated and analyzed: timeliness (to implement control measures), representation (an accurate picture of the temporal trend), sensitivity (identifying individual persons with disease, for treatment or quarantine) and specificity (excluding persons without it). Lecture 12, Slide 15. The considerations for setting it up run from the case definition and the purpose to the legal authority, data sources, frequency, population, confidentiality, analysis and dissemination. Lecture 12, Slides 16, 17.
Case surveillance is foundational: local and state public health departments collect data about a case or person with a disease or condition that poses a serious threat (infectious diseases, food-borne outbreaks, noninfectious conditions like lead poisoning); if it is notifiable, it is reported to the CDC. An indicator is a measurable factor used to estimate the size of a problem and the effects of interventions. Lecture 12, Slide 19.
| Kind of surveillance | How it works | Trade-off |
|---|---|---|
| Active | Staff regularly contact health care providers for data; often for specific purposes such as outbreaks or seasonal events | Most accurate, but most expensive |
| Passive | Relies on reports submitted by health care facilities and providers (including routine health information systems) | Most common, but less comprehensive; data quality is hard to control and it may lead to under-reporting |
| Sentinel | A prearranged group of reporting sources, normally providers, agrees to report all cases of specific conditions; a smaller representative group tracking on behalf of a much larger population | Trying to get ahead of an outbreak |
| Syndromic | Active or passive, with case definitions based entirely on clinical features (diarrhea instead of cholera, for example) | Most frequently found in developing countries |
Lecture 12, Slides 19, 20.
The Slide 25 list of uses of surveillance data Light touch
“I don’t want you to memorize this list.” [part 1, 29:10]
Read it for the shape: surveillance data are used for immediate detection (of epidemics, newly emerging problems, changes in practice and resistance), for periodic dissemination (magnitude and cost, control activities, risk factors, planning) and as stored information (natural history, research). Lecture 12, Slide 25.
3.6 · Objective 6 — Reportable disease Know it
She did not mention this objective in the review.
Not in her review, still examinable. She told the class in the lecture not to pay attention to the long list of notifiable diseases (below), but the objective asks for the definition, and that is short. Do not let the one instruction swallow the other. Lecture 12, Slides 21, 22.
A reportable (notifiable) disease is any disease that is required by law to be reported to government authorities. They are of public interest by reason of their contagiousness, severity or frequency: infectious diseases, bioterrorism agents, sexually transmitted diseases, and noninfectious conditions. Collecting the data lets authorities monitor the disease and gives early warning of outbreaks. In the United States collection is done through the CDC’s National Notifiable Diseases Surveillance System. Lecture 12, Slide 21.
| Group of reportable disease | Slide’s examples |
|---|---|
| Mandatory written report | Gonorrhea, salmonellosis |
| Mandatory report by telephone | Rubeola, pertussis |
| Report of total number of cases | Chickenpox, influenza |
| Cancer | Reported to state cancer registries |
A list of notifiable diseases is produced every year. Lecture 12, Slide 22.
The Slide 23 list of notifiable diseases Light touch
“Here’s a list I’m absolutely not requiring you to pay attention to” [part 1, 27:48]
The full current list of notifiable diseases, from anthrax to Zika. Lecture 12, Slide 23.
3.7 · Objective 7 — Measures of morbidity and mortality Know cold
“The different measures of morbidity and mortality.” [part 4, 19:58]
“You should know the difference between incidence and prevalence.” [part 1, 30:33]
The review only named this objective; the lecture is where she said what to know, and it was the incidence-prevalence distinction.
Morbidity refers to having a disease or symptom of disease, the level of disease in a population, or sometimes the risk of a disease; it is measured by incidence and prevalence. Mortality is the death rate, the number of deaths in a group at a particular time, referenced by age, sex or cause. Lecture 12, Slide 26.
| Incidence — the speedometer | Prevalence — the odometer | |
|---|---|---|
| Definition | The proportion or rate of persons who develop a condition during a particular time period | The proportion of persons who have a condition at or during a particular time period |
| Numerator | New cases that occurred during the period | All cases present during the period |
Prevalence depends on both incidence and duration. High prevalence may reflect high incidence, or prolonged survival without cure, or both; low prevalence may mean low incidence, a rapidly fatal process, or rapid recovery. Prevalence rather than incidence is often measured for chronic diseases such as diabetes or osteoarthritis, which last long and have onsets that are hard to pinpoint. Lecture 12, Slide 27.
The slide’s own test, worked. “Number of women reported with heart disease in Town A in a recent health survey, over the number of women residents of Town A” counts everyone who has it — prevalence. “Number of women newly diagnosed with heart disease in 2020, over the number of women residents on 1 July 2020” counts new cases in a period — incidence. Lecture 12, Slides 27, 28.
| Mortality rate | What it counts |
|---|---|
| Crude | Deaths from all causes in a population in a given time period |
| Cause-specific | Deaths from a specific cause in a population |
| Age-specific | Deaths in a specific age group |
| Infant | Infant deaths; used to compare health status between countries. The United States ranks 54th worldwide, much higher than most other developed nations, with considerable disparities by race and socioeconomic status |
| Maternal | Mortality associated with pregnancy |
Lecture 12, Slide 29. The case fatality rate is deaths over total cases; it may be overestimated at first, when the sickest cases are the ones hospitalized, and then underestimated as testing of mild cases increases. Lecture 12, Slide 59.
3.8 · Objective 8 — Association versus causation Know cold
“Association and causation, the [Hill’s] criteria.” [part 4, 20:04]
“Now, if I were to by any chance give you a scenario that gave you some information, you should be able to tell me whether something is going to be more of an association or a causation.” [part 3, 11:10–11:25]
In the lecture she described the exact form of question to expect: a scenario, and a judgment on whether it shows association or causation.
| Association | Causation |
|---|---|
| An identifiable relationship between an exposure and a disease. It implies that the exposure might cause the disease; exposures associated with a difference in disease risk are often called risk factors. Most often, public health interventions are designed on associations | Implies there is a true mechanism leading from exposure to disease. Finding an association does not make it causal |
Epidemiology does not determine the cause of a disease in a given individual; it determines the relationship between an exposure and the frequency of disease in populations, and causation is inferred from association and other factors. Lecture 12, Slide 43. An association can be due to chance, be spurious (an artifact), be confounded, be non-causal, or be causal Lecture 12, Slide 44. A cause is an event or condition that plays a role in producing a disease, and most diseases come from an interplay of factors, not one. Lecture 12, Slide 45.
| Hill’s criterion for causal inference | What it means |
|---|---|
| Consistency of findings | Demonstrated in multiple studies, across different populations, in differing circumstances, with different study designs Lecture 12, Slide 47. |
| Strength of association | Less likely to be due to chance or bias; a strong association has a relative risk that is very high or very low Lecture 12, Slide 48. |
| Biological gradient | A dose-response relationship: changes in exposure are related to a trend in relative risk; one of the most reliable indicators of causality Lecture 12, Slide 49. |
| Temporal sequence | Exposure must precede disease — and precede the latent period, in diseases that have one; chronic diseases often need long-term exposure Lecture 12, Slide 50. |
| Plausibility and coherence | The mechanism should be biologically plausible and must not contradict the known natural history and biology — though the relationship may be indirect, the data may not yet exist, and understanding may need reinterpreting Lecture 12, Slide 51. |
| Specificity of association | The exposure leads to a single or characteristic effect, or affects people with a specific susceptibility; easier to argue causation when specific, but many exposures cause several diseases Lecture 12, Slide 52. |
Lecture 12, Slide 46. The prevailing wisdom: most judgments of cause and effect are tentative and open to change with new evidence. Lecture 12, Slide 53.
How to answer her scenario. An exposure and a disease turning up together is an association. It moves toward causation as Hill’s criteria are met — and the one she singled out in the lecture is the dose-response gradient: “And of course the best data would be something that gave you that biological gradient” [part 3, 11:34], which the slide calls one of the most reliable indicators of causality.
3.9 · Objective 9 — Endemic, epidemic, pandemic, sporadic, herd immunity Know cold
“And then know that endemic, epidemic, pandemic, sporadic, herd immunity” [part 4, 20:10–20:13]
“These different kinds of epidemics can be graphed and show different patterns, which you should be able to identify.” [part 3, 13:47–13:54]
Two instructions: know the five terms (the review), and be able to identify the epidemic curves (the lecture).
| Term | Definition |
|---|---|
| Endemic | Diseases found at chronically low levels in a population |
| Sporadic | Diseases that occur at irregular intervals, or are isolated incidents |
| Epidemic | Diseases occurring in excess of what might be expected in a population, or as an uncontrolled spread in a community |
| Pandemic | Worldwide epidemics |
| Herd immunity | The cumulative number of immune persons in a population, or the percentage of the population immune; often discussed in relation to vaccination against a pathogen, but also affected by natural immunity from recovery Lecture 12, Slide 60. |
Lecture 12, Slide 54. Immunity itself is inherited, acquired or induced resistance to infection by a specific pathogen; resistance acquired from a previous infection comes from protective cellular and antibody responses. Lecture 12, Slide 60.
The epidemic curves — “which you should be able to identify”. The types, then what each one looks like on the slides’ graphs of cases by date of onset. Lecture 12, Slide 55.
| Type | Definition | What the slide’s graph shows |
|---|---|---|
| Common source: point | A group exposed to the same source over a short time (one incubation period) | Hepatitis A, 1978: a presumed index case (a food handler), then a single sharp rise and fall Lecture 12, Slide 56. |
| Common source: continuous | Exposure over a longer time (intermittent is the third common-source kind) | Diarrheal illness, 1989–1990: cases spread over weeks around water main breaks, falling only after a boil-water order and chlorination removed the source Lecture 12, Slide 56. |
| Propagated | Person-to-person transmission | Measles, 1970–1971: successive waves of cases, each rising higher Lecture 12, Slide 57. |
| Mixed | May start as a common source and then be propagated | Shigella at a music festival, 1988: cases among staff first, then a large peak among attendees Lecture 12, Slide 57. |
| Other | Often zoonotic or vector-borne | Lyme disease reported by year; West Nile encephalitis in New York City by week, falling after mosquito control began Lecture 12, Slide 58. |
The time slide gives the same distinction in words: a point source is localized and stationary; a propagated one reflects spreading infection and may be extended. Lecture 12, Slide 36.
R0, the basic reproduction number, is the number of cases directly generated by one case in a susceptible population without interventions; R, the effective reproduction number, is the number generated by one case with interventions or immunity. Lecture 12, Slide 59.
3.10 · Objective 10 — Applications of epidemiology Know it
“and then the fact that epidemiology gives us the evidence for policy development.” [part 4, 20:16]
Her last words in the review were about policy, and they match the slide’s phrase: evidence is one of four bases of policy (with values, ideology and politics), “not usually the main influence on policy, but worth fighting for” — and it is the main contribution of epidemiology. Epidemiological studies can bring major policy changes if they are rigorously conducted, reported and communicated. Lecture 12, Slide 72.
Not in her review, still examinable. The objective names five applications; her list named one. The other four are on the slides. Lecture 12, Slide 61.
| Application | What the slides say |
|---|---|
| Policy development | The policy cycle: assessment of population health; assessment of potential interventions and their evidence; policy choices (for example by computer modeling, then consensus); implementation with target goals and resources; evaluation Lecture 12, Slide 73. Worked example, youth smoking: adult smoking fell by the 1980s but youth smoking did not, until a 1994 Surgeon General’s report shifted the approach from individuals to the community; evidence that secondhand smoke was dangerous reframed it as a societal concern, leading to smoke-free public places, less advertising, less youth access and higher taxes Lecture 12, Slide 74. A public health approach runs surveillance, risk factor identification, intervention, evaluation and implementation Lecture 12, Slide 71. |
| Outbreak investigation | Establish the existence of an outbreak; prepare for field work; verify the diagnosis; define and identify cases; use descriptive epidemiology to orient the data; develop, evaluate and refine a hypothesis; implement control and prevention; communicate findings Lecture 12, Slide 62. Worked example, Legionnaires’ disease, 1976: an American Legion convention in Philadelphia, 221 cases and 34 deaths; the case-control study found time in the lobby of Hotel A was the risk factor, and in December a CDC laboratorian located the bacterium Lecture 12, Slides 64–68. Genomic epidemiology is now the critical tool here Lecture 12, Slide 69. |
| Social and behavioral issues | How income inequality, poverty, race and discrimination affect health, including access to care; how behavioral risk factors contribute to disease; and policy in these areas Lecture 12, Slide 75. |
| Environment | Environmental epidemiology: how environmental factors such as air and water pollution, or hazardous waste sites, affect human health Lecture 12, Slide 76. |
| Occupational health | How workers’ health is affected by workplace conditions and hazardous substances: how often workers are injured or ill, which groups are most affected, why, and how to reduce the risk through regulation Lecture 12, Slide 76. |
For noncommunicable disease the slide lists the steps: define the population, measure exposures and health indicators, sample, estimate associations, evaluate whether they are causal, assess causes working together, and assess external validity. Lecture 12, Slide 70.
What she said about the exam
Four things are worth taking from the review beyond its contents.
The objectives are the blueprint — except in Lecture 10. For Disorders in Immunity she read down the objective list, and her Epidemiology list follows that lecture’s objectives in order. For the Gram-positive bacilli she set the objectives aside in so many words — “those learning objectives are really, really general, so let’s go to the list of organisms” [part 4, 12:24–12:28] — so expect that lecture organism by organism: where the spore sits, what it needs to grow, what disease it causes, and what gives it away.
She asked more than she told. Most Lecture 7 and Lecture 10 items were put to the class as questions: which hypersensitivity, which form of anthrax, what a mixed infection is, what Listeria needs, what is characteristic of diphtheria. The questions she put to the room are the clearest signal of what she expects you to be able to answer, and they are the Know cold items above.
Lecture 12 was weighted in the lecture, not the review. It got under a minute at the end because she had just taught it. The stronger instructions — know the difference between incidence and prevalence, know genomic epidemiology, tell association from causation in a scenario, identify the epidemic curves — came during the lecture, and they are quoted in the items.
The review was one-sided by design. She reviewed her own three lectures. Nothing here says anything about the relative weight of Dr. Fair’s Lectures 8, 9, 11 and 13 on the exam — she was not the one who taught them.
Next steps: the full Exam 2 study guide covers all seven lectures, and the cram sheet condenses them. To test yourself on exactly this review, the two Webster Review quizzes (Set 2) give every item above a question in each set, with extra ones on the Know cold items.